Lance Steinberg
Psychiatry · Calabasas, CANPI 1487780532
Payments from drug & device makers
Across 307 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Tris Pharma Inc$1K
- Bausch Health US, LLC$420
- Supernus Pharmaceuticals, Inc.$396
- Takeda Pharmaceuticals U.S.A., Inc.$372
- Corium, LLC$275
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,768100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $1,292 |
| Tris Pharma Inc | 71 | $1,219 |
| Bausch Health US, LLC | 27 | $420 |
| Supernus Pharmaceuticals, Inc. | 16 | $396 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $372 |
| Corium, LLC | 13 | $275 |
| Vanda Pharmaceuticals Inc. | 9 | $233 |
| Neos Therapeutics, LP | 13 | $219 |
| Johnson & Johnson | 8 | $186 |
| Axsome Therapeutics, Inc. | 8 | $186 |
| Ironshore Pharmaceuticals Inc. | 9 | $167 |
| Collegium Pharmaceutical, Inc. | 9 | $151 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $139 |
| Eisai Inc. | 5 | $101 |
| Lundbeck LLC | 4 | $94 |
| Sunovion Pharmaceuticals Inc. | 6 | $84 |
| Neurocrine Biosciences, Inc. | 3 | $81 |
| Noven Therapeutics, LLC | 2 | $47 |
| Vertical Pharmaceuticals, LLC | 1 | $29 |
| Adlon Therapeutics L.p. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
How this compares
$5,784 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Wellbutrin XlBupropion Hcl | 13 | $32,602 |
| Effexor XrVenlafaxine Hcl | 12 | $15,641 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $6,616 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 24 | $2,102 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $1,676 |
| Duloxetine Hcl | 39 | $1,599 |
| Dextroamphetamine Sulfate | 11 | $1,117 |
| Fluoxetine Hcl | 17 | $543 |
| Methylphenidate Hcl | 16 | $505 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $482 |
| Bupropion XlBupropion Hcl | 23 | $436 |
| Sertraline Hcl | 21 | $311 |
| Mirtazapine | 18 | $295 |
| Lamotrigine | 24 | $289 |
| Bupropion Hcl SrBupropion Hcl | 15 | $179 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Calabasas
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.